10,811 Shares in Twist Bioscience Co. (NASDAQ:TWST) Purchased by Bayesian Capital Management LP

Bayesian Capital Management LP bought a new position in shares of Twist Bioscience Co. (NASDAQ:TWST - Free Report) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor bought 10,811 shares of the company's stock, valued at approximately $502,000.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in TWST. Van ECK Associates Corp increased its stake in shares of Twist Bioscience by 56.4% during the fourth quarter. Van ECK Associates Corp now owns 740 shares of the company's stock worth $34,000 after buying an additional 267 shares during the period. Wilmington Savings Fund Society FSB purchased a new stake in shares of Twist Bioscience during the 3rd quarter worth $34,000. US Bancorp DE grew its stake in shares of Twist Bioscience by 72.0% during the fourth quarter. US Bancorp DE now owns 1,436 shares of the company's stock worth $67,000 after purchasing an additional 601 shares in the last quarter. KBC Group NV increased its holdings in Twist Bioscience by 71.4% in the fourth quarter. KBC Group NV now owns 2,942 shares of the company's stock valued at $137,000 after buying an additional 1,226 shares during the last quarter. Finally, Blue Trust Inc. raised its stake in Twist Bioscience by 19.9% in the fourth quarter. Blue Trust Inc. now owns 4,567 shares of the company's stock valued at $206,000 after buying an additional 757 shares in the last quarter.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on TWST shares. Barclays lowered their target price on shares of Twist Bioscience from $58.00 to $45.00 and set an "overweight" rating for the company in a report on Thursday, April 10th. Scotiabank reaffirmed an "outperform" rating on shares of Twist Bioscience in a report on Tuesday, February 4th. JPMorgan Chase & Co. reduced their target price on Twist Bioscience from $40.00 to $33.00 and set an "underweight" rating for the company in a report on Tuesday, May 6th. Guggenheim reiterated a "buy" rating and issued a $50.00 price objective on shares of Twist Bioscience in a research note on Tuesday, May 6th. Finally, Robert W. Baird cut their target price on shares of Twist Bioscience from $54.00 to $44.00 and set an "outperform" rating on the stock in a report on Tuesday, May 6th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and eight have assigned a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $50.40.

Twist Bioscience Price Performance

Shares of NASDAQ TWST traded down $1.79 during trading on Friday, hitting $30.82. 1,158,651 shares of the company were exchanged, compared to its average volume of 968,895. The company has a debt-to-equity ratio of 0.03, a current ratio of 4.96 and a quick ratio of 4.62. Twist Bioscience Co. has a 1 year low of $30.72 and a 1 year high of $60.90. The company has a market cap of $1.85 billion, a price-to-earnings ratio of -9.12 and a beta of 2.54. The firm's fifty day moving average price is $38.63 and its 200 day moving average price is $43.66.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last released its quarterly earnings data on Monday, May 5th. The company reported ($0.66) EPS for the quarter, missing analysts' consensus estimates of ($0.56) by ($0.10). Twist Bioscience had a negative return on equity of 32.69% and a negative net margin of 59.76%. The company had revenue of $92.79 million for the quarter, compared to analysts' expectations of $92.00 million. On average, sell-side analysts expect that Twist Bioscience Co. will post -2.12 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Twist Bioscience news, SVP Paula Green sold 918 shares of the firm's stock in a transaction on Thursday, March 6th. The stock was sold at an average price of $40.91, for a total transaction of $37,555.38. Following the completion of the transaction, the senior vice president now owns 130,912 shares of the company's stock, valued at approximately $5,355,609.92. This trade represents a 0.70 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Emily M. Leproust sold 2,402 shares of the business's stock in a transaction on Thursday, March 6th. The stock was sold at an average price of $40.91, for a total value of $98,265.82. Following the completion of the transaction, the chief executive officer now directly owns 662,692 shares of the company's stock, valued at approximately $27,110,729.72. This trade represents a 0.36 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 18,991 shares of company stock valued at $742,654. 3.01% of the stock is owned by insiders.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.